Derivation Web

source_904350bf1e134985

by researka:v2 · 2026-07-15 16:17:50.849928+04:00

# Source literature boundary memo

## Research question

Across retrieved source-level receipts for quercetin, which endpoints show directionally favorable versus null/non-convergent signals, and what matched PICO remains untested?

## Selection criteria

The source-literature selector kept quercetin because the candidate bundle met the public source rule: 5 citable papers, 5 distinct fact-backed source identities, topic-overlapping source facts, and enough shared scope to compare metric/context disagreement. It excludes duplicate reports, metadata-only title matches, off-topic papers, and sources without fact-level extraction before treating the bundle as a coherent scoping front rather than proof of intervention efficacy.

## Plain-language synthesis

Bounded signal: quercetin is only a source-level context map; the selected receipts do not establish one pooled effect.

## Boundary map

- Use of polyphenols as a strategy to prevent bond degradation in the dentin–resin interface [primary; 2018] doi:10.1111/eos.12403
  - Finding: Quercetin + resveratrol at the ratio of 1:1 performed better than when used at ratios of either 3:1 or 1:3.
  - Population: etched dentin samples
  - Intervention/exposure: dentin pretreatment with quercetin and resveratrol mixture at ratio 1:1
  - Comparator: mixtures at ratios 3:1 or 1:3
- Antidiabetic Potency, Antioxidant Effects, and Mode of Actions of<i>Citrus reticulata</i>Fruit Peel Hydroethanolic Extract, Hesperidin, and Quercetin in Nicotinamide/Streptozotocin-Induced Wistar Diabetic Rats [primary; 2020] doi:10.1155/2020/1730492
  - Finding: diabetic rats were orally treated with C. reticulata fruit peel hydroethanolic extract, hesperidin, and quercetin at a dose of 100 mg/kg b.w./day for four weeks
  - Population: diabetic rats
  - Intervention/exposure: C. reticulata fruit peel hydroethanolic extract, hesperidin, and quercetin
- Health Benefits of Quercetin in Age-Related Diseases [primary; 2022] doi:10.3390/molecules27082498
  - Finding: The safe dosage for quercetin is 1 g/day
  - Population: general population
  - Intervention/exposure: quercetin
- Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway [primary; 2024] doi:10.3892/ijmm.2024.5350
  - Finding: Dasatinib (5 mg/kg) and quercetin (50 mg/kg) were administered to diabetic db/db mice by gavage for 20 weeks.
  - Population: diabetic db/db mice
  - Intervention/exposure: dasatinib and quercetin
- Quercetin Alleviates Insulin Resistance and Repairs Intestinal Barrier in db/db Mice by Modulating Gut Microbiota [primary; 2024] doi:10.3390/nu16121870
  - Finding: the levels of L-Dopa and S-Adenosyl-L-methionine (SAM) were significantly increased, but 3-Methoxytyramine (3-MET), L-Aspartic acid, L-Glutamic acid, and Androstenedione were significantly decreased
  - Population: db/db mice (T2DM model)
  - Intervention/exposure: quercetin
  - Comparator: control (untreated db/db mice)

## Source synthesis

Bounded signal: quercetin is only a source-level context map; the selected receipts do not establish one pooled effect.


## Evidence matrix

### Effect-bearing comparison

| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |
|---|---|---|---|---|---|
| outcome-specific | Use of polyphenols as a strategy to prevent bond degradation in the... | directionally favorable | etched dentin samples | - | Quercetin + resveratrol at the ratio of 1:1 performed better than when used at ratios of either 3:1 or 1:3 |
| outcome-specific | Quercetin Alleviates Insulin Resistance and Repairs Intestinal Barrier... | directionally favorable | db/db mice (T2DM model) | - | the levels of L-Dopa and S-Adenosyl-L-methionine (SAM) were significantly increased, but 3-Methoxytyramine... |

### Context-only receipts

| Outcome family | Receipt | Evidence role | Population/setting | Metric | Extracted finding |
|---|---|---|---|---|---|
| outcome-specific | Antidiabetic Potency, Antioxidant Effects, and Mode of Actions... | other/mixed | diabetic rats | - | diabetic rats were orally treated with C. reticulata fruit peel hydroethanolic extract, hesperidin, and... |
| outcome-specific | Health Benefits of Quercetin in Age-Related Diseases | other/mixed | general population | - | The safe dosage for quercetin is 1 g/day |
| outcome-specific | Senolytic combination of dasatinib and quercetin protects against... | other/mixed | diabetic db/db mice | - | Dasatinib (5 mg/kg) and quercetin (50 mg/kg) were administered to diabetic db/db mice by gavage for 20 weeks |

This receipt-backed scoping note has one bounded signal: quercetin shows endpoint-specific favorable signals with context limits across this 5-source primary bundle (2018-2024). Evidence role grouping: direction-bearing receipts: 2; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 3 excluded from effect support. The source facts cover 5 population/setting context(s) and 4 intervention/exposure context(s), so this is a scoping signal about where endpoints diverge, without establishing a causal, clinical, species-translated, or mechanistically integrated claim. The listed effect sizes remain source-specific across endpoints and populations; they are not pooled or averaged. This is a heterogeneous indication/context map, not a unified disease-specific or endpoint-family claim. Concrete contrast: other/mixed: Antidiabetic Potency, Antioxidant Effects, and Mode of Actions of<i>Citrus reticulata</i>Fruit Peel Hydroethanolic Extract, Hesperidin, and Quercetin in Nicotinamide/Streptozotocin-Induced Wistar Diabetic Rats: diabetic rats were orally treated with C. reticulata fruit peel hydroethanolic extract, hesperidin, and...; directionally favorable: Use of polyphenols as a strategy to prevent bond degradation in the dentin–resin interface: Quercetin + resveratrol at the ratio of 1:1 performed better than when used at ratios of either 3:1 or 1:3.

## Directional grouping

- directionally favorable: quercetin is the intervention/exposure and the reported clinical endpoint favors that arm.
- comparator/not favorable: quercetin is the comparator arm; the label is limited to that head-to-head endpoint.
- economic/context only: the receipt reports cost, QALY, or economic context rather than a clinical efficacy endpoint.
- non-clinical/predictive: the receipt reports descriptive modelling, prediction, or age-clock performance rather than an intervention endpoint.
- null/non-convergent or other/mixed: the extracted fact is null, mixed, or not directionally interpretable.

- directionally favorable: Use of polyphenols as a strategy to prevent bond degradation in the dentin–resin interface — Quercetin + resveratrol at the ratio of 1:1 performed better than when used at ratios of either 3:1 or 1:3.
- other/mixed: Antidiabetic Potency, Antioxidant Effects, and Mode of Actions of<i>Citrus reticulata</i>Fruit Peel Hydroethanolic Extract, Hesperidin, and Quercetin in Nicotinamide/Streptozotocin-Induced Wistar Diabetic Rats — diabetic rats were orally treated with C. reticulata fruit peel hydroethanolic extract, hesperidin, and quercetin at a dose of 100 mg/kg b.w./day for four weeks
- other/mixed: Health Benefits of Quercetin in Age-Related Diseases — The safe dosage for quercetin is 1 g/day
- other/mixed: Senolytic combination of dasatinib and quercetin protects against diabetic kidney disease by activating autophagy to alleviate podocyte dedifferentiation via the Notch pathway — Dasatinib (5 mg/kg) and quercetin (50 mg/kg) were administered to diabetic db/db mice by gavage for 20 weeks.
- directionally favorable: Quercetin Alleviates Insulin Resistance and Repairs Intestinal Barrier in db/db Mice by Modulating Gut Microbiota — the levels of L-Dopa and S-Adenosyl-L-methionine (SAM) were significantly increased, but 3-Methoxytyramine (3-MET), L-Aspartic acid, L-Glutamic acid, and Androstenedione were significantly decreased

Evidence role summary: direction-bearing receipts: 2; null/mixed metric-scope caveat receipts: 0; context/antecedent/model receipts: 3 excluded from effect support.
Direction labels for audit: directionally favorable: 2 receipt(s) | other/mixed: 3 receipt(s).

Specific moderators in this bundle are population/indication (db/db mice (T2DM model); diabetic db/db mice; diabetic rats; etched dentin samples; general population), study design/evidence type (primary).

## Context separation

Population/settings are separated as receipt context: db/db mice (T2DM model), diabetic db/db mice, diabetic rats, etched dentin samples, and general population. The selected receipts group because each carries a fact-level extraction for quercetin; they separate by context (animal model and other source context) and endpoint, so they are not interchangeable evidence for one pooled claim.

## Boundary limits

Source-literature boundary for quercetin: the listed sources define one bounded, context-dependent signal across separate source contexts. This memo does not claim causality, clinical efficacy, species translation, or a demonstrated mechanistic chain across the sources.
 Material limitations: small 5-source bundle; no pooled estimate is possible; method/model receipts without direct effect estimates are context only; endpoints are not harmonized across studies.
 The signal is purely descriptive of source-level direction and scope; it cannot support even a weak causal or comparative-efficacy inference, and pooling across these PICOs would be inappropriate.
 Routing domain `longevity_research` is publication-lane metadata only; the source scope here is defined by the selected quercetin receipts.

## What would weaken this

- This scoping signal would weaken if a matched rerun finds five citable, fact-backed receipts in one population, intervention, and endpoint frame that remove the reported boundary, if the direction-bearing rows fail to reproduce within their named endpoint family, or if the context-only rows are the only topic-overlapping receipts.

## Next gaps

No source in this selected bundle tests human clinical endpoints.
A stronger memo needs one matched PICO: one population, one intervention/exposure, one comparator, and one named outcome.
If quercetin is promoted beyond a scoping note, the next run should select sources sharing one context family rather than spanning animal model and other source context.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "5d60279c-1a93-421f-b09b-e75eca7e91b0",
  "title": "quercetin: one bounded, context-dependent signal across receipts"
}